Cannarella Rossella, Leanza Claudia, Crafa Andrea, Aversa Antonio, Condorelli Rosita A, Calogero Aldo E, La Vignera Sandro
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH 44106, USA.
J Clin Med. 2024 Sep 24;13(19):5666. doi: 10.3390/jcm13195666.
To study the effect of switching to a follicle-stimulating hormone (FSH) preparation other than that to which infertile male patients have not had an effective response. Seventy-four normogonadotropinemic, non-obstructive, oligozoospermic patients who were poor responders to the administration of highly purified FSH (hpFSH) (Group 1 (n = 22) and Group 3 (n = 15)) or to recombinant human FSH (rhFSH) (Group 2 (n = 22) and Group 4 (n = 15)) were selected for this prospective study. After 3 months of washout from treatment with the first FSH preparation of choice, rhFSH was administered to patients in Groups 1 and 4 and hpFSH to those in Groups 2 and 3. Serum luteinizing hormone, FSH, total testosterone levels, conventional sperm parameters, testicular volume, and the number of pregnancies were evaluated at study entry and after the first and second treatment cycles. Comparing treatment groups, the greatest improvement in sperm parameters was recorded in the groups of patients prescribed the switch in FSH preparation. Group 1 had the greatest benefit from therapy, with the highest pregnancy rate after the second treatment cycle. Indeed, eight couples achieved pregnancy (36.4%), compared to Groups 2 (n = 4; 18.2%), 3 (n = 1; 6.7%), and 4 (n = 2; 13.3%) ( = 0.04). The results of this study suggest that a therapeutic scheme involving the "switching" of the FSH preparation yields better results than a protocol using the same FSH preparation for six months. These findings, if confirmed by further studies, will help us better design a treatment strategy with FSH for infertile patients with oligozoospermia.
研究改用一种不育男性患者未曾产生有效反应的促卵泡激素(FSH)制剂的效果。选取74例促性腺激素正常、非梗阻性少精子症患者,这些患者对高纯度FSH(hpFSH)给药反应不佳(第1组(n = 22)和第3组(n = 15))或对重组人FSH(rhFSH)给药反应不佳(第2组(n = 22)和第4组(n = 15)),进行这项前瞻性研究。在用首选的第一种FSH制剂治疗洗脱3个月后,第1组和第4组患者给予rhFSH,第2组和第3组患者给予hpFSH。在研究开始时以及第一个和第二个治疗周期后,评估血清促黄体生成素、FSH、总睾酮水平、常规精子参数、睾丸体积和妊娠次数。比较各治疗组,在改用FSH制剂的患者组中,精子参数改善最大。第1组从治疗中获益最大,在第二个治疗周期后妊娠率最高。实际上,8对夫妇成功妊娠(36.4%),相比之下,第2组(n = 4;18.2%)、第3组(n = 1;6.7%)和第4组(n = 2;13.3%)(P = 0.04)。本研究结果表明,涉及FSH制剂“转换”的治疗方案比使用相同FSH制剂治疗6个月的方案效果更好。这些发现若得到进一步研究的证实,将有助于我们更好地设计针对少精子症不育患者的FSH治疗策略。